Evommune director granted 15,673 stock options

Evommune, Inc. director Arthur S. Kirsch received a grant of stock options covering 15,673 shares of common stock.

Rhea-AI Filing Summary

Evommune, Inc. director Arthur S. Kirsch received a grant of stock options covering 15,673 shares of common stock. The options have an exercise price of $19.82 per share and expire on June 1, 2036. Following this grant, he holds options on 15,673 shares directly.

The award vests at the earlier of the first anniversary of the grant date or Evommune’s next annual meeting of stockholders, as long as Kirsch continues to serve through that vesting date. This is a compensation-related grant, not an open‑market purchase or sale.

Insider Trade Summary

Grant/Award: 15,673 shares

Grant/Award 1 txn

Insider KIRSCH ARTHUR S

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to buy)	15,673	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to buy) — 15,673 contracts (Direct)

Footnotes (1)

1. F1. The shares subject to the option award shall vest at the earlier of (i) the first anniversary of the grant date and (ii) the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continuous service through such vesting date.

Key Figures

Option grant size: 15,673 shares Exercise price: $19.82 per share Expiration date: June 1, 2036 +1 more

4 metrics

Option grant size 15,673 shares Stock Option (Right to buy) award to director

Exercise price $19.82 per share Conversion or exercise price of options

Expiration date June 1, 2036 Option term end date

Post-grant derivative holdings 15,673 options Total derivative shares following transaction

Key Terms

Stock Option (Right to buy), exercise price, expiration date, transaction code A, +1 more

5 terms

Stock Option (Right to buy) financial

"security_title: Stock Option (Right to buy)"

exercise price financial

"conversion_or_exercise_price: 19.8200"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

expiration date financial

"expiration_date: 2036-06-01T00:00:00.000Z"

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

transaction code A regulatory

"transaction_code: A (Grant, award, or other acquisition)"

underlying security financial

"underlying_security_title: Common Stock"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Evommune (EVMN) director Arthur S. Kirsch report on this Form 4?

Arthur S. Kirsch reported receiving a stock option grant for 15,673 shares of Evommune common stock. The options are a compensation-related award, not an open-market trade, and give him the right to buy shares at a fixed exercise price.

What are the terms of Arthur S. Kirsch’s new Evommune (EVMN) stock options?

Kirsch’s options cover 15,673 underlying shares at an exercise price of $19.82 per share. They expire on June 1, 2036, providing a long-dated right to purchase Evommune common stock if the vesting conditions are satisfied.

How and when do Arthur S. Kirsch’s Evommune (EVMN) option awards vest?

The options vest at the earlier of the first anniversary of the grant date or Evommune’s next annual stockholder meeting. Vesting requires Kirsch to maintain continuous service with the company through the applicable vesting date, according to the reported footnote.

Did Arthur S. Kirsch buy or sell Evommune (EVMN) shares in the market?

No market buy or sell was reported. The Form 4 shows a grant of stock options classified as an acquisition under transaction code A. This is a compensation award, not an open‑market purchase or sale of existing Evommune shares.

How many Evommune (EVMN) options does Arthur S. Kirsch hold after this filing?

After the reported grant, Kirsch holds stock options on 15,673 shares of Evommune common stock directly. The filing does not list any additional derivative positions in the derivative summary, so only this new award is shown as outstanding.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/03/2026 - 08:03 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

KIRSCH ARTHUR S

(Last) (First) (Middle)

C/O EVOMMUNE, INC.

1891 PAGE MILL ROAD

(Street)

PALO ALTO CALIFORNIA 94304

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Evommune, Inc. [ EVMN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/02/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to buy)	$19.82	06/02/2026		A		15,673		(1)	06/01/2036	Common Stock	15,673	$0.00	15,673	D

Explanation of Responses:

1. The shares subject to the option award shall vest at the earlier of (i) the first anniversary of the grant date and (ii) the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continuous service through such vesting date.

Remarks:

	/s/ Gregory S. Moss, Attorney-in-Fact	06/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)